Event-Driven Stocks

RVL Pharmaceuticals plc

Healthcare · Pharmaceutical Preparations · L2 · SEC filings ↗ · Compare ⊕

Signs● 2 good● 3 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY22FY21FY20FY19FY18FY17
Revenue$49.7M$17.5M$27.8M$240.0M$263.7M$245.7M
Operating income−$59.0M−$82.8M−$90.7M−$280.7M−$98.5M−$52.1M
Net income−$51.7M−$64.9M−$79.6M−$270.9M−$109.7M−$43.0M
Total assets$128.5M$144.7M$370.9M$463.3M$795.6M$919.7M
Total liabilities$77.4M$67.9M$277.1M$348.5M$411.8M$484.0M
Equity$51.1M$76.7M$93.9M$114.7M$383.8M—
EPS (diluted)$-0.58$-0.96$-1.31———
Shares out.83.5M62.7M58.9M52.5M52.5M—

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2022
Operating margin
−118.6%
Net margin
−104.0%
Return on equity
−101.2%
Return on assets
−40.2%
Return on capital (ROCE)
−54.2%
Liabilities / assets
60.2%
Debt / equity
1.52×
Book value / share
$0.61
Revenue growth (YoY)
184.1%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2022
Altman Z″ (distress)
-14.93distress
Accruals / assets
−10.8%clean
Piotroski F-Score
4/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
50
/ 100
Profitability 0Growth 100Catalyst 33Earnings quality 67Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

● 1 severe● 3 warning● 2 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Revenue is growing year-over-year
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.